Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India

Rheumatology International
Jasmina AhluwaliaGurjeewan Garewal

Abstract

Twenty-seven children with systemic lupus erythematosus (SLE) were tested for antiphospholipid antibodies (APLA), i.e. lupus anticoagulant and immunoglobulin (Ig)G or IgM anticardiolipin antibodies (ACLA), with beta-2 glycoprotein I as cofactor, in a single-centre, prospective study over 2 years. Eighteen patients (67%) tested positively for one or the other APLA during the course of the study. Twelve children (44%) tested positively for IgG ACLA and ten (37%) for IgM ACLA, whereas eight (30%) were positive for lupus anticoagulant. In two patients with thrombosis, IgG anticardiolipin positivity was seen to be variable. Unlike the results of most other reports in the literature, lupus anticoagulant positivity was not consistently associated with thrombosis. A majority of the children (83%) tested positively for ACLA during disease activity. Immunoglobulin G and IgM ACLA positivity did not correlate significantly with disease status. The results of this prospective study would indicate that, though frequently present, APLA may be unable to be predictive of disease behaviour in children with SLE.

References

Jun 1, 1991·Archives of Disease in Childhood·M A Montes de OcaB Wechsler
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Apr 1, 1994·Archives of Pediatrics & Adolescent Medicine·A RavelliA Martini
Aug 6, 2000·British Journal of Haematology·M GreavesI Mackie

❮ Previous
Next ❯

Citations

Nov 30, 2010·Rheumatology International·Shano NaseemSurjit Singh
Apr 25, 2008·Pediatric Hematology and Oncology·Bacel Nseir, Jyoti Panicker
Mar 4, 2020·Current Rheumatology Reports·Arzu Soybilgic, Tadej Avcin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.